An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

NCT02680808 Phase 1 COMPLETED

Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate

Details

Lead sponsor	F2G Ltd
Phase	Phase 1
Status	COMPLETED
Enrolment	20
Start date	2016-01
Completion	2016-06

Conditions

• Invasive Aspergillosis

Interventions

• Midazolam with F901318

Primary outcomes

• area under concentration/time curve — 24 hours
  AUC0-24

Countries

United Kingdom